Table 2.
Adjusted mean values at baseline and progression stratified by treatment.
| Domain | Time point | Eribulin Mean (SD) BL N = 228 PD N = 208 |
DAC Mean (SD) BL N = 224 PD N = 191 |
Overall Mean (SD) BL N = 452 PD N = 399 |
p value |
|---|---|---|---|---|---|
| Global health score and functioning | |||||
| Global Health Status | Baseline | 65.2 (23.49) | 64.9 (20.63) | 65.1 (22.10) | 0.900 |
| Progression | 62.1 (23.32) | 56.1 (21.85) | 59.3 (22.81) | 0.008∗ | |
| Physical Functioning | Baseline | 76.6 (22.74) | 76.5 (20.37) | 76.6 (21.57) | 0.970 |
| Progression | 73.3 (22.69) | 65.8 (26.35) | 69.7 (24.77) | 0.002∗ | |
| Role Functioning | Baseline | 74.0 (28.70) | 74.2 (25.96) | 74.1 (27.35) | 0.925 |
| Progression | 65.0 (32.95) | 58.7 (31.61) | 62.0 (32.43) | 0.054 | |
| Emotional Functioning | Baseline | 75.5 (21.73) | 74.0 (22.72) | 74.7 (22.21) | 0.482 |
| Progression | 71.7 (26.39) | 69.4 (24.08) | 70.6 (25.30) | 0.365 | |
| Cognitive Functioning | Baseline | 84.6 (19.49) | 83.9 (21.39) | 84.2 (20.43) | 0.731 |
| Progression | 81.0 (23.02) | 78.7 (24.79) | 79.1 (23.88) | 0.337 | |
| Social Functioning | Baseline | 71.7 (29.97) | 73.3 (26.65) | 72.5 (28.36) | 0.554 |
| Progression | 68.5 (29.59) | 65.4 (28.94) | 67.0 (29.29) | 0.283 | |
| Symptoms Domains | |||||
| Fatigue | Baseline | 31.4 (25.48) | 32.0 (23.42) | 31.7 (24.46) | 0.788 |
| Progression | 39.8 (26.29) | 44.9 (28.38) | 42.3 (27.39) | 0.066 | |
| Nausea and Vomiting | Baseline | 7.5 (15.02) | 8.2 (18.05) | 7.9 (16.58) | 0.687 |
| Progression | 7.8 (14.64) | 13.7 (20.40) | 10.7 (17.85) | 0.001∗ | |
| Pain | Baseline | 26.6 (28.14) | 30.5 (28.30) | 28.5 (28.25) | 0.149 |
| Progression | 34.6 (29.89) | 38.7 (30.87) | 36.6 (30.39) | 0.175 | |
| Dyspnea | Baseline | 18.4 (24.89) | 18.8 (25.16) | 18.6 (24.99) | 0.865 |
| Progression | 22.2 (26.07) | 27.4 (29.61) | 24.7 (27.91) | 0.064 | |
| Insomnia | Baseline | 26.0 (28.02) | 27.5 (29.10) | 26.7 (28.54) | 0.570 |
| Progression | 26.7 (31.41) | 33.2 (29.12) | 29.8 (30.46) | 0.035∗ | |
| Appetite Loss | Baseline | 16.8 (25.71) | 18.3 (28.62) | 17.6 (27.17) | 0.555 |
| Progression | 19.6 (27.26) | 29.5 (32.58) | 24.3 (30.30) | 0.001∗ | |
| Constipation | Baseline | 17.6 (25.70) | 15.0 (23.94) | 16.3 (24.85) | 0.276 |
| Progression | 20.4 (27.36) | 22.9 (28.11) | 21.6 (27.72) | 0.367 | |
| Diarrhea | Baseline | 9.3 (19.89) | 10.3 (21.79) | 9.8 (20.83) | 0.622 |
| Progression | 13.4 (22.96) | 10.3 (21.19) | 11.9 (22.15) | 0.168 | |
| Financial Difficulties | Baseline | 24.3 (32.78) | 25.7 (32.27) | 25.0 (32.50) | 0.669 |
| Progression | 29.8 (35.87) | 29.1 (32.35) | 29.5 (34.19) | 0.847 |
∗ indicates p values that are less than 0.05 and are considered statistically significant. DAC: dacarbazine.